Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Prodrugs as Drug Candidates for the Treatment of Ischemic Disorders: Insights into NO-Releasing Prodrug Biotransformation and Hemoglobin–NO Biochemistry
Guoyan Xu(Children's Hospital of Philadelphia), Martin K. Safo(Virginia Commonwealth University), Mostafa H. Ahmed(Virginia Commonwealth University), Mohini S. Ghatge(Children's Hospital of Philadelphia), Tanvi Deshpande(Virginia Commonwealth University), Abdelsattar M. Omar(Al-Azhar University), Akul Y. Mehta(Hadassah Medical Center), Yan Zhang(Virginia Commonwealth University), Osheiza Abdulmalik(Children's Hospital of Philadelphia), Jürgen Venitz(National Cancer Institute)
Cited by 12
Related Papers
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
2‐Methoxyestradiol, a Promising Anticancer Agent
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2003|276
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244
Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia
|Nature Communications|2016|212
GlyGen: Computational and Informatics Resources for Glycoscience
|Glycobiology|2019|207